Relmada (RLMD): Aims to Improve the Effectiveness and Safety of Pain Treatment

Destiny A. Lopez  |

According to the World Health Organization, diseases of the central nervous system effect nearly 2 billion people around the world. The most common ailments relating to the CNS are depression and pain. Between the two, antidepressants, such as Trofanil and Prozac, is the largest market segment in regards to the treatment of depression. Moreover, the pain relief market sees $13 billion in sales per year. Although the markets are among the largest within the treatment sectors, issues still remain regarding effectiveness and safety for patients. Relmada Therapeutics (RLMD), a bio-pharmaceutical company, is looking to address these unmet medical needs.

Check out this company at the upcoming Sidoti Emerging Growth Convention.

Headquartered in New York City, Relmada is dedicated to addressing the unmet medical needs within pain treatment by developing novel versions of drug products together with new molecules.

or company technology, project, etc. It’s portfolio of product candidates aims to treat various diseases that attack the central nervous system. According to the company’s official website, the candidates are as follows:

  • REL-1015/LevoCap ER, an extended release, abuse resistant form of broad spectrum opioid levorphanol currently in phase 3.
  • REL-1028/BuTab, the first traditional oral tablet form of buprenorphine.
  • REL-1021/MepiGel, a topical gel dosage form of local anesthetic mepivacaine currently in phase two development.

The company’s lead drug candidate, REL-1017/d-Methadone, is a novel NMDA antagonist for the treatment of depression and neuropathic pain currently in stage 2 development. The candidate is described by as the company’s “most-advanced new chemical entity.” This past June, the company announced its Notice of Allowance for U.S. Patent covering d-Methadone.

"This is a key milestone for Relmada that significantly strengthen Relmada's positon overall patent portfolio and support our continuing development program for d-Methadone, which has shown the potential to offer efficacy benefits similar to ketamine in the treatment of depression and other psychiatric disorders, but with significantly reduced risk of toxicity based on three completed Phase I studies," said Sergio Traversa, CEO of Relmada. "We look forward to initiating a Phase II proof-of-concept study with d-Methadone in depression as soon as feasible."

In recent weeks, Relmada has been very active on the conference circuit. In September, the company presented at the 2016 Ladenburg Thalmann Healthcare Conference where Traversa presented. Also, earlier this month, Dr. Richard Mangano, the company's chief scientific officer, participated in a panel of thought leaders regarding N-methyl-D-aspartate (NMDA) receptor antagonists held at the Neuro Advance Boston Conference.

Currently, Relmada, as they continue to work towards developing and bringing their drug candidate portfolio to the market, is scheduled to present at the 15th Annual BIO Investor Forum October 18-19, 2016. Check out this company at the upcoming Sidoti Emerging Growth Convention. Check out Relmada’s first R&D day, held May 4, 2016.

To learn more about Relmada, visit

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Symbol Name Price Change % Volume
RLMD Relmada Therapeutics Inc 2.47 0.02 0.82 7,289



Symbol Last Price Change % Change






INTERVIEW: CEO Jorge Fernandez - iBlades's Sam Mitchell interview iBlades CEO, Jorge Fernandez